Jin-Ho Choi

Dr. Jin-Ho Choi

National Cancer Center, Goyang-si, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2024 in Annals of Coloproctology
Verified
Journal Article
Open access
PDF file
HRHyo Seon Ryu
Hyo Seon Ryu
HKHyun Jung Kim
Hyun Jung Kim
WJWoong Bae Ji
Woong Bae Ji
BKByung Chang Kim
Byung Chang Kim
JKJi Hun Kim
Ji Hun Kim
KCKorean Colon Cancer Multidisciplinary Committee
Korean Colon Cancer Multidisciplinary Committee
Colorectal cancer is the third most common cancer in Korea and the third leading cause of death from cancer. Treatment outcomes for colon cancer are steadily improving due to national health screening programs with advances in diagnostic methods, surgical techniques, and therapeutic agents.. The Korea Colon Cancer Multidisciplinary (KCCM) Committee intends to provide professionals who treat colon cancer with the most up-to-date, evidence-based practice guidelines to improve outcomes and help them make decisions that reflect their patients’ values and preferences. These guidelines have been established by consensus reached by the KCCM Guideline Committee based on a systematic literature review and evidence synthesis and by considering the national health insurance system in real clinical practice settings. Each recommendation is presented with a recommendation strength and level of evidence based on the consensus of the committee.

5 August 2020 in The Korean Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
PDF file
HYHee Chul Yang
Hee Chul Yang
JCJin-Ho Choi
Jin-Ho Choi
MKMoon Soo Kim
Moon Soo Kim
JLJong Mog Lee
Jong Mog Lee
Hee Chul Yang, M.D., Ph.D., Jin Ho Choi, M.D., Moon Soo Kim, M.D., Jong Mog Lee, M.D.. Korean J Thorac Cardiovasc Surg 2020;53:226-32. https://doi.org/10.5090/kjtcs.2020.53.4.226

14 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SKSunshin Kim
Sunshin Kim
YLYoungjoo Lee
Youngjoo Lee
BSBo Ram Song
Bo Ram Song
HSHanna Sim
Hanna Sim
EKEun Hye Kang
Eun Hye Kang
JHJi-Youn Han
Ji-Youn Han
Intratumor heterogeneity leads to different responses to targeted therapies, even within patients whose tumors harbor identical driver oncogenes. This study examined clinical outcomes according to a patient-derived cell (PDC)-based drug sensitivity test in lung cancer patients treated with targeted therapies. From 487 lung cancers, 397 PDCs were established with a success rate of 82%. In 139 PDCs from advanced non-small-cell lung cancer (NSCLC) patients receiving targeted therapies, the standardized area under the curve (AUC) values for the drugs was significantly correlated with their tumor response (p = 0.002). Among 59 chemo-naive EGFR/ALK-positive NSCLC patients, the PDC non-responders showed a significantly inferior response rate (RR) and progression-free survival (PFS) for the targeted drugs than the PDC responders (RR, 25% vs. 78%, p = 0.011; median PFS, 3.4 months [95% confidence interval (CI), 2.8–4.1] vs. 11.8 months [95% CI, 6.5–17.0], p < 0.001). Of 25 EGFR-positive NSCLC patients re-challenged with EGFR inhibitors, the PDC responder showed a higher RR than the PDC non-responder (42% vs. 15%). Four patients with wild-type EGFR or uncommon EGFR-mutant NSCLC were treated with EGFR inhibitors based on their favorable PDC response to EGFR inhibitors, and two patients showed dramatic responses. Therefore, the PDC-based drug sensitivity test results were significantly associated with clinical outcomes in patients with EGFR- or ALK-positive NSCLC. It may be helpful for predicting individual heterogenous clinical outcomes beyond genomic alterations.

18 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JCJin-Ho Choi
Jin-Ho Choi
JLJong Mog Lee
Jong Mog Lee
MKMoon Soo Kim
Moon Soo Kim
YLYoungjoo Lee
Youngjoo Lee
YSYang-Gun Suh
Yang-Gun Suh
SMSung Ho Moon
Sung Ho Moon
Background: Proton beam therapy (PBT), as a neoadjuvant chemoradiotherapy (nCRT) modality, is expected to result in better outcomes than photon-based radiotherapy (RT) for esophageal cancer, particularly adenocarcinoma. This study reports the results of nCRT for locally advanced esophageal squamous cell carcinoma (ESCC) using both modalities. Methods: We retrospectively reviewed the records of patients who underwent nCRT for ESCC between 2001 and 2020. A median of 41.4 Gy or cobalt gray equivalents of radiation was delivered using either photons or protons, with concurrent chemotherapy. Dosimetric and clinical parameters were compared between the two groups. Results: Of the 31 patients, the lungs and heart of the proton group (n = 15) were exposed to significantly less radiation compared to the photon group (n = 16). No significant differences in short-term postoperative outcomes or lymphocyte count were observed between the groups, and there were no significant differences between the photon and proton groups in 2-year overall survival (67.8% vs. 68.6%, p = 0.867) or 2-year disease-free survival (33.3% vs. 34.5%, p = 0.749), with a median follow-up of 17 months. Conclusions: PBT provided a significant dosimetric benefit over photon-based RT during nCRT for ESCC; however, it did not improve clinical outcomes.

22 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EOEun Sang Oh
Eun Sang Oh
SMSung Ho Moon
Sung Ho Moon
YLYoungjoo Lee
Youngjoo Lee
BABeung-Chul AHN
Beung-Chul AHN
JLJong Yeul Lee
Jong Yeul Lee
TKTae Hyun Kim
Tae Hyun Kim
Recently, proton beam therapy (PBT) has gathered attention for improving outcomes and reducing toxicities in various cancers; however, the evidence for esophageal squamous cell carcinoma (ESCC) is lacking. Our study retrospectively evaluated the outcomes of PBT for ESCC patients at a single institute. The patients treated with PBT between November 2015 and February 2022 were included in the study, excluding those with distant metastases or those that had undertaken prior treatment for esophageal cancer (EC). The 3 year overall survival (OS) and progression-free survival (PFS) rates were calculated based on stage grouping. The patterns of failure, salvage treatment outcomes, and toxicity profiles were analyzed. The median follow-up was 35.1 months, and 132 patients were analyzed. The 3 year OS and PFS rates for the stages I, II, and III disease cases were 81.0%, 62.9%, and 51.3%; and 70.6%, 71.8%, and 39.8%, respectively. Nineteen patients presented isolated local progression, ten patients underwent appropriate salvage procedures, and nine were successfully salvaged. One patient with isolated regional progression was also salvaged. No cases of grade ≥ 4 lymphopenia were observed. One patient had grade 4 pericardial effusion and esophageal fistula. For the patients with ESCC, PBT is an effective treatment in terms of the survival outcomes and toxicities.

1 January 2022 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
HYHee Chul Yang
Hee Chul Yang
MKMoon Soo Kim
Moon Soo Kim
JLJong Mog Lee
Jong Mog Lee
JCJin-Ho Choi
Jin-Ho Choi
SPSang-Yoon Park
Sang-Yoon Park
Yang HC, et al. J Gynecol Oncol. 2021 Oct;33(1):e6. https://doi.org/10.3802/jgo.2022.33.e6